

Dr Pascal Clayette heads the Immune-Pharmacology & BioSafety Dept. of Bertin-Pharma (CEA, Fontenay aux Roses, France). Since 1988, his research published in more than 80 peer-reviewed articles concerns the evaluation (efficacy & safety, non clinical & clinical) of new therapeutical solutions against infection, cancer, autoimmune and neurodegenerative diseases (including prions) and of their modes of action. He is also involved in the questions of safety of medical devices and, for some of these topics, he was or is in several expert groups of the French regulatory agency (ANSM) and member of scientific committees of certain companies.